TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment for Adolescents With Depression Study (TADS)
Brief Summary: TADS is designed to compare the effectiveness of established treatments for teenagers suffering from major depressive disorder (MDD). The treatments are: psychotherapy ("talking therapy"); medication; and the combination of psychotherapy and medication. Altogether, 432 teenagers (both males and females) ages 12 to 17, will take part in this study at 12 sites in the United States.

The TADS design will provide answers to the following questions: What is the long-term effectiveness of medication treatment of teenagers who have major depression? What is the long-term effectiveness of a specific psychotherapy ("talking therapy) in the treatment of teenagers who have major depression? How does medication treatment compare with psychotherapy in terms of effectiveness, tolerability and teenager and family acceptance? And, What is the cost-effectiveness of medication, psychotherapy and combined treatments?

The medication being used in this study is called fluoxetine. Fluoxetine is also known as Prozac. Research has shown that medications like Prozac help depression in young persons. Fluoxetine has been approved by the FDA for use in the treatment of child and adolescent (ages 7 to 17 years) depression.

The psychotherapy or "talking therapy" being used in this study is called Cognitive Behavioral Therapy (CBT). CBT is a talking therapy that will teach both the teenager and his or her family member (e.g., parent) new skills to cope better with depression. Specific topics include education about depression and the causes of depression, setting goals, monitoring mood, increasing pleasant activities, social problem-solving, correcting negative thinking, negotiation, compromise and assertiveness. CBT sessions may also help with resolving disagreements as they affect families.


Options:
A: Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Psychotherapy; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive behavioral therapy (CBT), Drug: Drug therapy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Drug therapy | Intervention Type: BEHAVIORAL; Name: Cognitive behavioral therapy (CBT); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Drug therapy; Assigned to Arm(s): 1, 2
C: Arm Label: Escitalopram; Type: EXPERIMENTAL; Interventions: Drug: Escitalopram | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): Escitalopram | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Active, 1; Type: EXPERIMENTAL; Interventions: Drug: Sertraline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Sertraline; Assigned to Arm(s): Active, 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pharmacological Association of the Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism on Blood Pressure and Cardiovascular Risk in Relation to Anti-hypertensive Treatment
Brief Summary: To examine whether the association between selected hypertensive genes and combined fatal coronary heart disease and nonfatal myocardial infarction in high-risk hypertensives is modified by the type of antihypertensive treatment, leading to differential risks of coronary heart disease.


Options:
A: Arm Label: Chlorthalidone; Type: N/A; Interventions: Drug: Chlorthalidone | Arm Label: Amlodipine; Type: N/A; Interventions: Drug: Amlodipine | Arm Label: Lisinopril; Type: N/A; Interventions: Drug: Lisinopril | Arm Label: Doxazosin; Type: N/A; Interventions: Drug: Doxazosin | Intervention Type: DRUG; Name: Chlorthalidone; Assigned to Arm(s): Chlorthalidone | Intervention Type: DRUG; Name: Lisinopril; Assigned to Arm(s): Lisinopril | Intervention Type: DRUG; Name: Amlodipine; Assigned to Arm(s): Amlodipine | Intervention Type: DRUG; Name: Doxazosin; Assigned to Arm(s): Doxazosin
B: Arm Label: Candesartan; Type: EXPERIMENTAL; Interventions: Drug: candesartan, Drug: nifedipine, long acting, Drug: metoprolol, long-acting | Arm Label: Lisinopril; Type: EXPERIMENTAL; Interventions: Drug: lisinopril, Drug: nifedipine, long acting, Drug: metoprolol, long-acting | Arm Label: HCTZ; Type: ACTIVE_COMPARATOR; Interventions: Drug: hydrochlorothiazide | Intervention Type: DRUG; Name: candesartan; Assigned to Arm(s): Candesartan | Intervention Type: DRUG; Name: lisinopril; Assigned to Arm(s): Lisinopril | Intervention Type: DRUG; Name: hydrochlorothiazide; Assigned to Arm(s): HCTZ | Intervention Type: DRUG; Name: nifedipine, long acting; Assigned to Arm(s): Candesartan, Lisinopril | Intervention Type: DRUG; Name: metoprolol, long-acting; Assigned to Arm(s): Candesartan, Lisinopril
C: Intervention Type: DRUG; Name: Inhibitors, ACE; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: amlodipine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: lisinopril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: doxazosin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: chlorthalidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: pravastatin; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: MK0954, /Duration of Treatment : 5 Years; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator : atenolol /Duration of Treatment : 5 Years; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Trial to Determine the Efficacy of AIDSVAX B/E Vaccine in Intravenous Drug Users in Bangkok, Thailand
Brief Summary: The purpose of this study is to determine if the vaccine, AIDSVAX B/E, will protect intravenous drug users from becoming infected with HIV.


Options:
A: Intervention Type: BIOLOGICAL; Name: MN rgp120/HIV-1 and A244 rgp120/HIV-1; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Screening for intimate partner violence | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Screening for intimate partner violence; Assigned to Arm(s): 1
C: Arm Label: FEM-CARE; Type: EXPERIMENTAL; Interventions: Behavioral: FEM-CARE | Arm Label: Health Promotion; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Health Promotion | Intervention Type: BEHAVIORAL; Name: FEM-CARE; Assigned to Arm(s): FEM-CARE | Intervention Type: BEHAVIORAL; Name: Health Promotion; Assigned to Arm(s): Health Promotion
D: Arm Label: Extended-release naltrexone (XR-NTX); Type: ACTIVE_COMPARATOR; Interventions: Drug: Extended-Release Naltrexone | Arm Label: Motivational Enhancement Counseling Only; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Motivational Enhancement Counseling | Intervention Type: DRUG; Name: Extended-Release Naltrexone; Assigned to Arm(s): Extended-release naltrexone (XR-NTX) | Intervention Type: BEHAVIORAL; Name: Motivational Enhancement Counseling; Assigned to Arm(s): Motivational Enhancement Counseling Only

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Trial to Determine the Efficacy of AIDSVAX B/E Vaccine in Intravenous Drug Users in Bangkok, Thailand
Brief Summary: The purpose of this study is to determine if the vaccine, AIDSVAX B/E, will protect intravenous drug users from becoming infected with HIV.


Options:
A: Intervention Type: BIOLOGICAL; Name: MN rgp120/HIV-1 and A244 rgp120/HIV-1; Assigned to Arm(s): N/A
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Methadone | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methadone | Intervention Type: DRUG; Name: Methadone; Assigned to Arm(s): A, B
C: Arm Label: Parolee Comprehensive Care + Phone Coach; Type: EXPERIMENTAL; Interventions: Behavioral: Parolee Comprehensive Care + Phone Coach | Arm Label: Parolee Brief HBV program + Phone Coach; Type: EXPERIMENTAL; Interventions: Behavioral: Parolee Brief HBV Program + Phone Coach | Arm Label: Usual Care Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care Group | Intervention Type: BEHAVIORAL; Name: Parolee Comprehensive Care + Phone Coach; Assigned to Arm(s): Parolee Comprehensive Care + Phone Coach | Intervention Type: BEHAVIORAL; Name: Parolee Brief HBV Program + Phone Coach; Assigned to Arm(s): Parolee Brief HBV program + Phone Coach | Intervention Type: BEHAVIORAL; Name: Usual Care Group; Assigned to Arm(s): Usual Care Group
D: Arm Label: Recovery management intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Recovery management | Intervention Type: BEHAVIORAL; Name: Recovery management; Assigned to Arm(s): Recovery management intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Concomitant and Adjuvant Temozolomide and Radiotherapy for Newly Diagnosed Glioblastoma Multiforme - A Randomized Phase III Study
Brief Summary: RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if radiation therapy is more effective with or without temozolomide for glioblastoma multiforme.

PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without temozolomide in treating patients who have newly diagnosed glioblastoma multiforme.


Options:
A: Arm Label: Vaccination; Type: EXPERIMENTAL; Interventions: Biological: autologous dendritic cells | Intervention Type: BIOLOGICAL; Name: autologous dendritic cells; Assigned to Arm(s): Vaccination
B: Intervention Type: DRUG; Name: temozolomide; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A
C: Arm Label: Radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Radiotherapy of the partial brain. | Arm Label: Temozolomide; Type: EXPERIMENTAL; Interventions: Drug: Temozolomide | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): Temozolomide | Intervention Type: RADIATION; Name: Radiotherapy of the partial brain.; Assigned to Arm(s): Radiotherapy
D: Arm Label: Rindopepimut/GM-CSF plus Temozolomide; Type: EXPERIMENTAL; Interventions: Drug: Rindopepimut (CDX-110) with GM-CSF, Drug: Temozolomide | Arm Label: KLH plus Temozolomide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Temozolomide, Drug: KLH | Intervention Type: DRUG; Name: Rindopepimut (CDX-110) with GM-CSF; Assigned to Arm(s): Rindopepimut/GM-CSF plus Temozolomide | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): KLH plus Temozolomide, Rindopepimut/GM-CSF plus Temozolomide | Intervention Type: DRUG; Name: KLH; Assigned to Arm(s): KLH plus Temozolomide

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Concomitant and Adjuvant Temozolomide and Radiotherapy for Newly Diagnosed Glioblastoma Multiforme - A Randomized Phase III Study
Brief Summary: RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if radiation therapy is more effective with or without temozolomide for glioblastoma multiforme.

PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without temozolomide in treating patients who have newly diagnosed glioblastoma multiforme.


Options:
A: Intervention Type: DRUG; Name: temozolomide; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A
B: Arm Label: Cediranib & Gefitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: cediranib maleate, Drug: gefitinib | Arm Label: Cediranbib & placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: cediranib maleate, Drug: Placebo | Intervention Type: DRUG; Name: cediranib maleate; Assigned to Arm(s): Cediranbib & placebo, Cediranib & Gefitinib | Intervention Type: DRUG; Name: gefitinib; Assigned to Arm(s): Cediranib & Gefitinib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cediranbib & placebo
C: Arm Label: Temozolomide; Type: ACTIVE_COMPARATOR; Interventions: Drug: temozolomide, Genetic: DNA methylation analysis, Procedure: quality-of-life assessment | Arm Label: Radiation; Type: ACTIVE_COMPARATOR; Interventions: Genetic: DNA methylation analysis, Procedure: quality-of-life assessment, Radiation: Radiation | Intervention Type: DRUG; Name: temozolomide; Assigned to Arm(s): Temozolomide | Intervention Type: GENETIC; Name: DNA methylation analysis; Assigned to Arm(s): Radiation, Temozolomide | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): Radiation, Temozolomide | Intervention Type: RADIATION; Name: Radiation; Assigned to Arm(s): Radiation
D: Arm Label: O6-BG + BCNU + Radiation Therapy; Type: EXPERIMENTAL; Interventions: Drug: carmustine, Radiation: radiation therapy, Drug: O6-Benzylguanine | Arm Label: BCNU + Radiation Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: carmustine, Radiation: radiation therapy | Intervention Type: DRUG; Name: carmustine; Assigned to Arm(s): BCNU + Radiation Therapy, O6-BG + BCNU + Radiation Therapy | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): BCNU + Radiation Therapy, O6-BG + BCNU + Radiation Therapy | Intervention Type: DRUG; Name: O6-Benzylguanine; Assigned to Arm(s): O6-BG + BCNU + Radiation Therapy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Concomitant and Adjuvant Temozolomide and Radiotherapy for Newly Diagnosed Glioblastoma Multiforme - A Randomized Phase III Study
Brief Summary: RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if radiation therapy is more effective with or without temozolomide for glioblastoma multiforme.

PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without temozolomide in treating patients who have newly diagnosed glioblastoma multiforme.


Options:
A: Intervention Type: DRUG; Name: temozolomide; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A
B: Arm Label: Specialised palliative care (SPC) group; Type: EXPERIMENTAL; Interventions: Other: Specialised palliative care (SPC) | Arm Label: Standard care group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Specialised palliative care (SPC); Assigned to Arm(s): Specialised palliative care (SPC) group
C: Arm Label: Early entry group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Early palliative care intervention | Arm Label: Later entry group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Later entry group | Intervention Type: BEHAVIORAL; Name: Later entry group; Assigned to Arm(s): Later entry group | Intervention Type: BEHAVIORAL; Name: Early palliative care intervention; Assigned to Arm(s): Early entry group
D: Arm Label: Early Palliative Care Referral; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Early Palliative Care Referral | Arm Label: Conventional Cancer Care; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Early Palliative Care Referral | Intervention Type: BEHAVIORAL; Name: Early Palliative Care Referral; Assigned to Arm(s): Conventional Cancer Care, Early Palliative Care Referral

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Concomitant and Adjuvant Temozolomide and Radiotherapy for Newly Diagnosed Glioblastoma Multiforme - A Randomized Phase III Study
Brief Summary: RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if radiation therapy is more effective with or without temozolomide for glioblastoma multiforme.

PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without temozolomide in treating patients who have newly diagnosed glioblastoma multiforme.


Options:
A: Intervention Type: DRUG; Name: temozolomide; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A
B: Arm Label: Radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Radiotherapy of the partial brain. | Arm Label: Temozolomide; Type: EXPERIMENTAL; Interventions: Drug: Temozolomide | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): Temozolomide | Intervention Type: RADIATION; Name: Radiotherapy of the partial brain.; Assigned to Arm(s): Radiotherapy
C: Intervention Type: DRUG; Name: lomustine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: procarbazine hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A
D: Arm Label: Temozolomide; Type: ACTIVE_COMPARATOR; Interventions: Drug: temozolomide, Genetic: DNA methylation analysis, Procedure: quality-of-life assessment | Arm Label: Radiation; Type: ACTIVE_COMPARATOR; Interventions: Genetic: DNA methylation analysis, Procedure: quality-of-life assessment, Radiation: Radiation | Intervention Type: DRUG; Name: temozolomide; Assigned to Arm(s): Temozolomide | Intervention Type: GENETIC; Name: DNA methylation analysis; Assigned to Arm(s): Radiation, Temozolomide | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): Radiation, Temozolomide | Intervention Type: RADIATION; Name: Radiation; Assigned to Arm(s): Radiation

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Selenium and Vitamin E Cancer Prevention Trial (SELECT) for Prostate Cancer
Brief Summary: RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. It is not yet known which regimen of selenium and/or vitamin E may be more effective in preventing prostate cancer.

PURPOSE: Randomized phase III trial to determine the effectiveness of selenium and vitamin E, either alone or together, in preventing prostate cancer.


Options:
A: Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin C; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin E; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: beta-carotene; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: folic acid/Vitamin B6/Vitamin B12; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: N/A; Interventions: N/A | Arm Label: 2; Type: N/A; Interventions: N/A | Arm Label: 3; Type: N/A; Interventions: N/A | Arm Label: 4; Type: N/A; Interventions: N/A
C: Arm Label: Vitamin E + selenium placebo; Type: EXPERIMENTAL; Interventions: Drug: Vitamin E, Other: selenium placebo | Arm Label: Selenium + vitamin E placebo; Type: EXPERIMENTAL; Interventions: Drug: Selenium, Other: Vitamin E placebo | Arm Label: Vitamin E + selenium; Type: EXPERIMENTAL; Interventions: Drug: Vitamin E, Drug: Selenium | Arm Label: Vitamin E placebo + selenium placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Vitamin E placebo, Other: selenium placebo | Intervention Type: DRUG; Name: Vitamin E; Assigned to Arm(s): Vitamin E + selenium, Vitamin E + selenium placebo | Intervention Type: DRUG; Name: Selenium; Assigned to Arm(s): Selenium + vitamin E placebo, Vitamin E + selenium | Intervention Type: OTHER; Name: Vitamin E placebo; Assigned to Arm(s): Selenium + vitamin E placebo, Vitamin E placebo + selenium placebo | Intervention Type: OTHER; Name: selenium placebo; Assigned to Arm(s): Vitamin E + selenium placebo, Vitamin E placebo + selenium placebo
D: Arm Label: Vitamin E; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin E | Arm Label: Vitamin C; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin C | Arm Label: Multivitamin; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Multivitamin | Arm Label: Beta-carotene; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Beta-carotene | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin E; Assigned to Arm(s): Vitamin E | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin C; Assigned to Arm(s): Vitamin C | Intervention Type: DIETARY_SUPPLEMENT; Name: Multivitamin; Assigned to Arm(s): Multivitamin | Intervention Type: DIETARY_SUPPLEMENT; Name: Beta-carotene; Assigned to Arm(s): Beta-carotene

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Selenium and Vitamin E Cancer Prevention Trial (SELECT) for Prostate Cancer
Brief Summary: RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. It is not yet known which regimen of selenium and/or vitamin E may be more effective in preventing prostate cancer.

PURPOSE: Randomized phase III trial to determine the effectiveness of selenium and vitamin E, either alone or together, in preventing prostate cancer.


Options:
A: Arm Label: Vitamin E + selenium placebo; Type: EXPERIMENTAL; Interventions: Drug: Vitamin E, Other: selenium placebo | Arm Label: Selenium + vitamin E placebo; Type: EXPERIMENTAL; Interventions: Drug: Selenium, Other: Vitamin E placebo | Arm Label: Vitamin E + selenium; Type: EXPERIMENTAL; Interventions: Drug: Vitamin E, Drug: Selenium | Arm Label: Vitamin E placebo + selenium placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Vitamin E placebo, Other: selenium placebo | Intervention Type: DRUG; Name: Vitamin E; Assigned to Arm(s): Vitamin E + selenium, Vitamin E + selenium placebo | Intervention Type: DRUG; Name: Selenium; Assigned to Arm(s): Selenium + vitamin E placebo, Vitamin E + selenium | Intervention Type: OTHER; Name: Vitamin E placebo; Assigned to Arm(s): Selenium + vitamin E placebo, Vitamin E placebo + selenium placebo | Intervention Type: OTHER; Name: selenium placebo; Assigned to Arm(s): Vitamin E + selenium placebo, Vitamin E placebo + selenium placebo
B: Arm Label: Nutriceutical formulation; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Nutriceutical formulation | Arm Label: Placebo 1; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Placebo 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Nutriceutical formulation; Assigned to Arm(s): Nutriceutical formulation | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo 1, Placebo 2
C: Arm Label: PGZ; Type: EXPERIMENTAL; Interventions: Drug: pioglitazone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: pioglitazone; Assigned to Arm(s): PGZ | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Vitamin E; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin E | Arm Label: Vitamin C; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin C | Arm Label: Multivitamin; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Multivitamin | Arm Label: Beta-carotene; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Beta-carotene | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin E; Assigned to Arm(s): Vitamin E | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin C; Assigned to Arm(s): Vitamin C | Intervention Type: DIETARY_SUPPLEMENT; Name: Multivitamin; Assigned to Arm(s): Multivitamin | Intervention Type: DIETARY_SUPPLEMENT; Name: Beta-carotene; Assigned to Arm(s): Beta-carotene

Answer: A